RLAY
Income statement / Annual
Last year (2023), Relay Therapeutics, Inc.'s total revenue was $25.55 M,
an increase of 1,749.82% from the previous year.
In 2023, Relay Therapeutics, Inc.'s net income was -$341.97 M.
See Relay Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
| Operating Revenue |
$25.55 M
|
$1.38 M
|
$3.03 M
|
$82.65 M
|
$0.00
|
$0.00
|
| Cost of Revenue |
$5.27 M |
$4.13 M |
$3.93 M |
$3.55 M |
$2.85 M |
$2.15 M |
| Gross Profit |
$20.28 M |
-$2.75 M |
-$896,000.00 |
$79.11 M |
-$2.85 M |
-$2.15 M |
| Gross Profit Ratio |
0.79 |
-1.99 |
-0.3 |
0.96 |
0 |
0 |
| Research and Development
Expenses |
$330.02 M
|
$246.36 M
|
$172.65 M
|
$99.86 M
|
$70.31 M
|
$41.03 M
|
| General & Administrative
Expenses |
$74.95 M
|
$65.98 M
|
$57.39 M
|
$38.59 M
|
$13.74 M
|
$8.86 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$74.95 M
|
$65.98 M
|
$57.39 M
|
$38.59 M
|
$13.74 M
|
$8.86 M
|
| Other Expenses |
$0.00 |
-$20,000.00 |
-$4,000.00 |
-$16,000.00 |
-$58,000.00 |
-$9,000.00 |
| Operating Expenses |
$398.55 M |
$312.33 M |
$230.04 M |
$138.45 M |
$84.05 M |
$49.89 M |
| Cost And Expenses |
$398.55 M |
$312.33 M |
$230.04 M |
$138.45 M |
$84.05 M |
$49.89 M |
| Interest Income |
$31.05 M |
$8.79 M |
$830,000.00 |
$3.40 M |
$8.80 M |
$1.11 M |
| Interest Expense |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$5.27 M
|
$4.13 M
|
$3.93 M
|
$3.55 M
|
$2.85 M
|
$2.15 M
|
| EBITDA |
-$374.15 M
|
-$306.82 M
|
-$222.18 M
|
-$52.25 M
|
-$81.20 M
|
-$47.74 M
|
| EBITDA Ratio |
-14.65 |
-233.62 |
-29.49 |
-0.63 |
0 |
0 |
| Operating Income Ratio
|
-14.6
|
-216.71
|
-120.4
|
-0.68
|
0
|
0
|
| Total Other
Income/Expenses Net |
$31.03 M
|
$8.77 M
|
$826,000.00
|
$3.38 M
|
$8.74 M
|
$1.10 M
|
| Income Before Tax |
-$341.97 M |
-$290.51 M |
-$363.87 M |
-$52.41 M |
-$75.31 M |
-$48.79 M |
| Income Before Tax Ratio
|
-13.39
|
-210.36
|
-120.13
|
-0.63
|
0
|
0
|
| Income Tax Expense |
$0.00 |
-$36.25 M |
$132.94 M |
-$3.40 M |
-$8.80 M |
$1.10 M |
| Net Income |
-$341.97 M |
-$254.26 M |
-$496.81 M |
-$49.01 M |
-$66.50 M |
-$48.79 M |
| Net Income Ratio |
-13.39 |
-184.11 |
-164.02 |
-0.59 |
0 |
0 |
| EPS |
-2.79 |
-2.27 |
-5.22 |
-1.15 |
-15.53 |
-19.63 |
| EPS Diluted |
-2.79 |
-2.27 |
-5.22 |
-1.15 |
-15.53 |
-19.63 |
| Weighted Average Shares
Out |
$122.58 M
|
$112.23 M
|
$95.14 M
|
$42.62 M
|
$4.28 M
|
$2.49 M
|
| Weighted Average Shares
Out Diluted |
$122.58 M
|
$112.23 M
|
$95.14 M
|
$42.62 M
|
$4.28 M
|
$2.49 M
|
| Link |
|
|
|
|
|
|
